Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has received a consensus rating of “Moderate Buy” from the twenty research firms that are covering the firm, Marketbeat reports. Seven analysts have rated the stock with a hold recommendation and thirteen have issued a buy recommendation on the company. The average 1 year price target among […]
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the twenty analysts that are covering the firm, MarketBeat reports. Seven research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average 1 year price objective among […]
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its price target increased by Piper Sandler from $210.00 to $217.00 in a research note issued on Thursday, Benzinga reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. Piper Sandler’s price target points to a potential upside of 15.63% from the company’s current […]
Wells Fargo & Company initiated coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a report issued on Friday morning, Marketbeat reports. The brokerage issued an equal weight rating and a $171.00 target price on the biopharmaceutical company’s stock. Other analysts have also recently issued reports about the company. BMO Capital Markets reduced […]
HC Wainwright reissued their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a report published on Wednesday, Benzinga reports. The brokerage currently has a $395.00 price objective on the biopharmaceutical company’s stock. Other equities analysts also recently issued reports about the company. Sanford C. Bernstein dropped their price target on Alnylam […]